Clinical trial: Gluten microchallenge with wheat-based starch hydrolysates in coeliac disease patients - A randomized, double-blind, placebo-controlled study to evaluate safety

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 10, 2008, Pages 1240-1248

  Kaukinen, K ^b   Salmi, T ^b   Collin, P ^b   Huhtala, H ^c   Karja Lahdensuu T ^a   Maki M ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUTEN; MALTODEXTRIN; PLACEBO; STARCH HYDROLYSATE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CELIAC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; INTESTINE VILLUS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MEMBRANE STRUCTURE; MUCOSA INFLAMMATION; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEROLOGY; SMALL INTESTINE MUCOSA; WHEAT;

ADULT; AGED; AGED, 80 AND OVER; CELIAC DISEASE; DOUBLE-BLIND METHOD; FEMALE; GLUTENS; HUMANS; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MIDDLE AGED; STARCH; TRITICUM; YOUNG ADULT;

EID: 54049139961     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03832.x     Document Type: Article

References (32)

1. Mäki M, Mustalahti K, Kokkonen J, et al. Prevalence of celiac disease among children in Finland. N Engl J Med 2003 348: 2517 24.
2. West J, Logan RF, Hill PG, et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003 52: 960 5.
3. Collin P, Thorell L, Kaukinen K, Mäki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment Pharmacol Ther 2004 19: 1277 83.
4. Hischenhuber C, Crevel R, Jarry B, et al. Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease. Aliment Pharmacol Ther 2006 23: 559 75.
5. Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007 85: 160 6.
6. Ciclitira PJ, Cerio R, Ellis HJ, Maxton D, Nelufer JM, Macartney JM. Evaluation of a gliadin-containing gluten-free product in coeliac patients. Hum Nutr Clin Nutr 1985 39C: 303 8.
7. Ejderhamn J, Veress B, Strandvik B. The long-term effect of continual ingestion of wheat starch-containing gluten-free products in coeliac patients. In: Kumar PJ, ed. Coeliac Disease: One Hundred Years. Leeds: Leeds University Press, 1988: 294 7.
8. Kaukinen K, Collin P, Holm K, et al. Wheat starch-containing gluten-free flour products in the treatment of coeliac disease and dermatitis herpetiformis. A long-term follow-up study. Scand J Gastroenterol 1999 34: 164 9.
9. Peräaho M, Kaukinen K, Paasikivi K, et al. Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease. Prospective and randomized study. Aliment Pharmacol Ther 2003 17: 587 94.
10. Selby WS, Painter D, Collins A, Faulkner-Hogg KB, Loblay RH. Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten. Scand J Gastroenterol 1999 34: 909 14.
11. Auricchio S, Troncone R. Effects of small amounts of gluten in the diet of coeliac patients. Panminerva Med 1991 33: 83 5.
12. Chartrand LJ, Russo PA, Duhaime AG, Seidman EG. Wheat starch intolerance in patients with celiac disease. J Am Diet Assoc 1997 97: 612 8.
13. Ferre S, Garcia E, Mendez E. Measurement of hydrolysed gliadins by a competitive ELISA based on monoclonal antibody R5: analysis of syrups and beers. In: Stern M, ed. Proceedings of the 18th Meeting Working Group on Prolamin Analysis and Toxicity. Zwickau: Verlag Wissenschaftliche Scripten, 2003: 65 9.
14. Directive 2003/89/EC of the European Parliament and the Council of 10 November 2003 amending Directive 2000/13/EC as regards indication of the ingredients present in foodstuffs. Available at: http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2003:308:0015:0018:EN:PDF. 2003. Last accessed 27 August 2008.
15. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet 2000 356: 203 8.
16. Lee SK, Lo W, Memeo L, Rotterdam H, Green PHR. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc 2003 57: 187 91.
17. Biagi F, Campanella J, Martucci S, et al. A milligram of gluten a day keeps the mucosal recovery away: a case report. Nutr Rev 2004 62: 360 3.
18. Bardella MT, Velio P, Cesana BM, et al. Coeliac disease: a histological follow-up study. Histopathology 2007 50: 465 71.
19. Kaukinen K, Peraaho M, Lindfors K, et al. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007 25: 1237 45.
20. Kuitunen P, Kosnai I, Savilahti E. Morphometric study of the jejunal mucosa in various childhood enteropathies with special reference to intraepithelial lymphocytes. J Pediatr Gastroenterol Nutr 1982 1: 525 31.
21. Järvinen TT, Kaukinen K, Laurila K, et al. Intraepithelial lymphocytes in celiac disease. Am J Gastroenterol 2003 98: 1332 7.
22. Sulkanen S, Halttunen T, Laurila K, et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 1998 115: 1322 8.
23. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993 28: 681 7.
24. Svedlund J, Sjödin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988 33: 129 34.
25. Hallert C, Grännö C, Grant C, Hulten S, Midhagen G, Ström M. Quality of life of adult coeliac patients treated for 10 years. Scand J Gastroenterol 1998 33: 993 8.
26. Mustalahti K, Lohiniemi S, Collin P, Vuolteenaho N, Laippala P, Mäki M. Gluten-free diet and quality of life in patients with screen-detected celiac disease. Eff Clin Pract 2002 5: 105 13.
27. Ciclitira PJ, Evans DJ, Fagg NL, Lennox ES, Dowling RH. Clinical testing of gliadin fractions in coeliac patients. Clin Sci 1984 66: 357 64.
28. Sturgess R, Day P, Ellis HJ, et al. Wheat peptide challenge in coeliac disease. Lancet 1994 343: 758 61.
29. Vahedi K, Mascart F, Mary JY, et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003 98: 1079 87.
30. European Food Safety Authority. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies [NDA] related to a notification from AAC on wheat-based glucose syrups including dextrose pursuant to Article 6, paragraph 11 of Directive 2000/13/EC. Available at: http://www.efsa.europa.eu/ EFSA/efsa_locale-1178620753812_1178623594476.htm. 2007. Last accessed 27 August 2008.
31. Codex Draft Revised Standard for Gluten-free Foods. Draft Revised Codex Standard for Foods for Special Dietary Use for Persons Intolerant to Gluten (at Step 8 of the Procedure). Available at: http://www.csaceliacs.org/documents/ CodexStandardforGF.pdf. 2007. Last accessed 27 August 2008.
32. Commission Directive 2007/68/EC of 27 November 2007 amending Annex IIIa to Directive 2000/13/EC of the European Parliament and of the Council as regards certain food ingredients. Available at: http://eur-lex.europa.eu/LexUriServ/ site/en/oj/2007/l_310/l_31020071128en00110014.pdf. 2007. Last accessed 27 August 2008.